Literature DB >> 33677205

Sensory processing and P300 event-related potential correlates of stimulant response in children with attention-deficit/hyperactivity disorder: A critical review.

Virginia Peisch1, Tara Rutter2, Carol L Wilkinson3, Anne B Arnett4.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder associated with considerable impairment in psychiatric and functional domains. Although stimulant medication can reduce core symptoms of inattention, hyperactivity, and impulsivity, a subgroup of patients does not respond to this intervention. A precision medicine approach has been proposed, whereby biomarkers are used to identify an effective treatment approach for a given individual. This review synthesizes the existing literature on event-related potential (ERP) correlates of stimulant response in children diagnosed with ADHD, with the goal of evaluating the potential for ERP to inform precision medicine care in this population. Forty-three articles were examined and results tentatively suggest that stimulant medications normalize the amplitude of the P300 component, and this is also associated with behavioral improvement. In contrast, results generally indicate that stimulants do not significantly alter early processing components, although there are some exceptions to this finding. Implications for research, theory, and clinical work are considered and concrete recommendations for future directions are provided. While recognizing limitations of existing literature (e.g., homogenous samples, variable methodologies), we conclude that ERP methods represent a promising approach for precision medicine care of patients with ADHD.
Copyright © 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADHD; Biomarker; ERP; Pediatric; Pharmacological treatment

Mesh:

Substances:

Year:  2021        PMID: 33677205      PMCID: PMC7981253          DOI: 10.1016/j.clinph.2021.01.015

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  92 in total

Review 1.  A review of electrophysiology in attention-deficit/hyperactivity disorder: I. Qualitative and quantitative electroencephalography.

Authors:  Robert J Barry; Adam R Clarke; Stuart J Johnstone
Journal:  Clin Neurophysiol       Date:  2003-02       Impact factor: 3.708

2.  Responses to methylphenidate in adolescent AD/HD: evidence from concurrently recorded autonomic (EDA) and central (EEG and ERP) measures.

Authors:  Daniel F Hermens; Leanne M Williams; Simon Clarke; Michael Kohn; Nicholas Cooper; Evian Gordon
Journal:  Int J Psychophysiol       Date:  2005-10       Impact factor: 2.997

Review 3.  Event-related brain potentials in the study of visual selective attention.

Authors:  S A Hillyard; L Anllo-Vento
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

4.  EEG-defined subtypes of children with attention-deficit/hyperactivity disorder.

Authors:  A R Clarke; R J Barry; R McCarthy; M Selikowitz
Journal:  Clin Neurophysiol       Date:  2001-11       Impact factor: 3.708

5.  Personalized Medicine in ADHD and Depression: Use of Pharmaco-EEG.

Authors:  Martijn Arns; Sebastian Olbrich
Journal:  Curr Top Behav Neurosci       Date:  2014

Review 6.  Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects.

Authors:  T Frodl; N Skokauskas
Journal:  Acta Psychiatr Scand       Date:  2011-11-28       Impact factor: 6.392

7.  The effect of methylphenidate on response inhibition and the event-related potential of children with attention deficit/hyperactivity disorder.

Authors:  Samantha J Broyd; Stuart J Johnstone; Robert J Barry; Adam R Clarke; Rory McCarthy; Mark Selikowitz; Carlie A Lawrence
Journal:  Int J Psychophysiol       Date:  2005-10       Impact factor: 2.997

8.  Methylphenidate does not modify the impact of response frequency or stimulus sequence on performance and event-related potentials of children with attention deficit hyperactivity disorder.

Authors:  J A Smithee; R Klorman; J T Brumaghim; A D Borgstedt
Journal:  J Abnorm Child Psychol       Date:  1998-08

9.  Predicting Clinical Gains and Side Effects of Stimulant Medication in Pediatric Attention-Deficit/Hyperactivity Disorder by Combining Measures From qEEG and ERPs in a Cued GO/NOGO Task.

Authors:  Geir Ogrim; Juri D Kropotov
Journal:  Clin EEG Neurosci       Date:  2018-06-25       Impact factor: 1.843

10.  An event-related potential investigation of the acute effects of aerobic and coordinative exercise on inhibitory control in children with ADHD.

Authors:  Sebastian Ludyga; Serge Brand; Markus Gerber; Peter Weber; Mark Brotzmann; Fahimeh Habibifar; Uwe Pühse
Journal:  Dev Cogn Neurosci       Date:  2017-10-27       Impact factor: 6.464

View more
  4 in total

1.  Neural Markers of Methylphenidate Response in Children With Attention Deficit Hyperactivity Disorder.

Authors:  Anne B Arnett; Tara M Rutter; Mark A Stein
Journal:  Front Behav Neurosci       Date:  2022-05-06       Impact factor: 3.617

2.  Prolonged P300 Latency in Antipsychotic-Free Subjects with At-Risk Mental States Who Later Developed Schizophrenia.

Authors:  Yuko Higuchi; Tomiki Sumiyoshi; Takahiro Tateno; Suguru Nakajima; Daiki Sasabayashi; Shimako Nishiyama; Yuko Mizukami; Tsutomu Takahashi; Michio Suzuki
Journal:  J Pers Med       Date:  2021-04-21

3.  P300 Modulation via Transcranial Alternating Current Stimulation in Adult Attention-Deficit/Hyperactivity Disorder: A Crossover Study.

Authors:  Kyra Kannen; Behrem Aslan; Cindy Boetzel; Christoph S Herrmann; Silke Lux; Helena Rosen; Benjamin Selaskowski; Annika Wiebe; Alexandra Philipsen; Niclas Braun
Journal:  Front Psychiatry       Date:  2022-07-18       Impact factor: 5.435

Review 4.  Treatment biomarkers for ADHD: Taking stock and moving forward.

Authors:  Giorgia Michelini; Luke J Norman; Philip Shaw; Sandra K Loo
Journal:  Transl Psychiatry       Date:  2022-10-12       Impact factor: 7.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.